المؤلفون: Antonarakis, ES, Piulats, JM, Gross-Goupil, M, Goh, J, Ojamaa, K, Hoimes, CJ, Vaishampayan, U, Berger, R, Sezer, A, Alanko, T, de Wit, R, Li, CD, Omlin, A, Procopio, G, Fukasawa, S, Tabata, KI, Park, SH, Feyerabend, S, Drake, CG, Wu, HY, Qiu, P, Kim, J, Poehlein, C, de Bono, JS

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(5):395-405

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:143312962Test

المؤلفون: Roubaud, Guilhem, Özgüroğlu, M., Penel, Nicolas, Matsubara, N., Mehra, N., Kolinsky, M. P., Procopio, G., Feyerabend, S., Joung, J. Y., Gravis, Gwenaelle, Nishimura, K., Gedye, C., Padua, C., Shore, N., Thiery-Vuillemin, Antoine, Saad, F., Van Alphen, R., Carducci, M. A., Desai, C., Brickel, N., Poehlein, C., Del Rosario, P., Fizazi, Karim

المساهمون: Université de Lille, CHU Lille, Institut Bergonié Bordeaux, Centre Régional de Lutte contre le Cancer Oscar Lambret Lille UNICANCER/Lille, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Institut Paoli-Calmettes IPC, Centre Hospitalier Régional Universitaire de Besançon CHRU Besançon, Institut Gustave Roussy IGR

مصطلحات موضوعية: PROfound, Metastatic castration-resistant prostate, cancer, Olaparib, Safety, Adverse-event management

وصف الملف: application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf

العلاقة: European Journal of Cancer; Eur J Cancer; http://hdl.handle.net/20.500.12210/90084Test

الإتاحة: https://doi.org/20.500.12210/90084Test
https://hdl.handle.net/20.500.12210/90084Test

المؤلفون: de Wit, R, Wülfing, C, Castellano, D, Kramer, G, Eymard, J-C, Sternberg, C N, Fizazi, K, Tombal, B, Bamias, A, Carles, J, Iacovelli, R, Melichar, B, Sverrisdóttir, Á, Theodore, C, Feyerabend, S, Helissey, C, Foster, M C, Ozatilgan, A, Geffriaud-Ricouard, C, de Bono, J

المساهمون: 1Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: r.dewit@erasmusmc.nl. 2Department of Urology, Asklepios Tumorzentrum, Hamburg, Germany. 3Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain. 4Department of Urology, Medical University of Vienna, Vienna, Austria. 5Department of Medical Oncology, Institute Jean Godinot, Reims, France. 6Division of Hematology and Medical Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA. 7Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France, University of Paris Saclay, Saint-Aubin, France. 8Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium. 9Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece. 10Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. 11Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata (AOUI), Verona, Italy, Department of Medical Oncology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy. 12Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic. 13Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland. 14Department of Oncology, Foch Hospital, Suresnes, France. 15Studienpraxis Urologie, Nürtingen, Germany. 16Hôpital d'Instruction des Armées Bégin, Saint Mandé, France. 17Global Medical Oncology, Sanofi, Cambridge, USA. 18Europe Medical Oncology, Sanofi, Paris, France. 19Division of Clinical Studies, The Institute of Cancer Research, London, UK, Prostate Targeted Therapy Group, Royal Marsden Hospital, London, UK.

المصدر: ESMO open ; 6 ; 5 ; 100241 ; MAO12 ; England

مصطلحات موضوعية: abiraterone, cabazitaxel, enzalutamide, metastatic castration-resistant prostate cancer, neutrophil-to-lymphocyte ratio, prognostic factor

العلاقة: https://www.sciencedirect.com/science/article/pii/S2059702921002027?via%3DihubTest; de Wit R, Wülfing C, Castellano D, et al. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. ESMO Open. 2021;6(5):100241. doi:10.1016/j.esmoop.2021.100241; http://hdl.handle.net/2336/622016Test; ESMO open

الإتاحة: https://doi.org/10.1016/j.esmoop.2021.100241Test
http://hdl.handle.net/2336/622016Test

المؤلفون: Oudard, S., Beuzeboc, P., Voog, E., Barthelemy, P., Thiery-Vuillemin, A., Bennamoun, M., Hasbini, A., Aldabbagh, K., Saldana, C., Sevin, E., Amela, Y.E., Von Amsberg, G., Houede, N., Besson, D., Feyerabend, S., Boegemann, M., Pfister, D., Schostak, M., Huillard, O., Helissey, C.

المصدر: Annals of Oncology ; volume 33, page S1164-S1165 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.1495Test
https://api.elsevier.com/content/article/PII:S0923753422033464?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422033464?httpAccept=text/plainTest

المؤلفون: Grivas, P., Loriot, Y., Morales Barrera, Rafael, Teo, M. Y., Zakharia, Y., Feyerabend, S.

المساهمون: Institut Català de la Salut, Grivas P Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Seattle Cancer Care Alliance, Seattle, WA 98109, USA. Loriot Y Department of Medicine, Gustave Roussy Cancer Campus, INSERM U981, Université Paris-Saclay, 94800 Villejuif, France. Morales-Barrera R Vall d’Hebron Hospital Universitari, Barcelona, Spain. Teo MY Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Zakharia Y Division of Hematology, Oncology, and Blood and Marrow Transplant, University of Iowa and Holden Comprehensive Cancer Center, Iowa City, IA 52242, USA. Feyerabend S Studienpraxis Urologie, 72622 Nürtingen, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Bufeta - Càncer - Tractament, Inhibidors enzimàtics - Ús terapèutic - Eficàcia, DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Poly(ADP-ribose) Polymerase Inhibitors, Other subheadings::Other subheadings::Other subheadings::/administration & dosage, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias urológicas::neoplasias de la vejiga, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de poli(ADP-ribosa) polimerasas, Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación

وصف الملف: application/pdf

العلاقة: BMC Cancer;21; https://doi.org/10.1186/s12885-021-08085-zTest; Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, et al. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer. 2021 May 24;21:593.; https://hdl.handle.net/11351/7057Test; 000657731100001

الإتاحة: https://doi.org/10.1186/s12885-021-08085-zTest
https://hdl.handle.net/11351/7057Test

المؤلفون: de Wit, R, Wülfing, C, Castellano, D, Kramer, G, Eymard, J-C, Sternberg, C N, Fizazi, K, Tombal, Bertrand, Bamias, A, Carles, J, Iacovelli, R, Melichar, B, Sverrisdóttir, Ã, Theodore, C, Feyerabend, S, Helissey, C, Foster, M C, Ozatilgan, A, Geffriaud-Ricouard, C, de Bono, J

المساهمون: UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie

المصدر: ESMO open, Vol. 6, no. 5, p. 100241 [1-9] (2021)

مصطلحات موضوعية: abiraterone, cabazitaxel, enzalutamide, metastatic castration-resistant prostate cancer, neutrophil-to-lymphocyte ratio, prognostic factor

العلاقة: info:eu-repo/grantAgreement/Sanofi Genzyme//; boreal:250296; http://hdl.handle.net/2078.1/250296Test; info:pmid/34450475; urn:EISSN:2059-7029

الإتاحة: https://doi.org/10.1016/j.esmoop.2021.100241Test
http://hdl.handle.net/2078.1/250296Test

المؤلفون: Gratzke, C.J., Fizazi, K., Shore, N.D., Smith, M.R., Feyerabend, S., Grabbert, M., Carles, J., Lebret, T., Vjaters, E., Werbrouck, P., Miskic, M., Ortiz, J., Schmall, A., Le Berre, M.A., Verholen, F.

المصدر: Annals of Oncology ; volume 32, page S664 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1143Test
https://api.elsevier.com/content/article/PII:S092375342103372X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S092375342103372X?httpAccept=text/plainTest

المؤلفون: Antonarakis, E.S., Piulats, J.M., Gross-Goupil, M., Goh, J.C., Vaishampayan, U.N., De Wit, R., Alanko, T.V., Fukasawa, S., Tabata, K., Feyerabend, S., Berger, R., Ojamaa, K., Hoimes, C.J., Sezer, A., Omlin, A.G., Yachnin, J., Niu, C., Poehlein, C.H., Schloss, C., de Bono, J.S.

المساهمون: GlaxoSmithKline, Meso Scale Diagnostics, Merck, Janssen Pharmaceuticals, Roche, Merck Sharp and Dohme, Sanofi, Bayer Fund, AstraZeneca, AbbVie, Pfizer, Astellas Pharma US, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries

المصدر: Annals of Oncology ; volume 32, page S651-S652 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1124Test
https://api.elsevier.com/content/article/PII:S0923753421033536?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421033536?httpAccept=text/plainTest

المؤلفون: Shen, J., Chowdhury, S., Agarwal, N., Karsh, L.I., Oudard, S., Gartrell, B.A., Feyerabend, S., Saad, F., Pieczonka, C.M., Chi, K.N., Brookman-May, S.D., Rooney, B., Bhaumik, A., Londhe, A., McCarthy, S.A., Bevans, K.B., Mundle, S.D., Small, E.J., Smith, M.R., Graff, J.N.

المصدر: Annals of Oncology ; volume 32, page S656-S657 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1131Test
https://api.elsevier.com/content/article/PII:S0923753421033603?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421033603?httpAccept=text/plainTest

المؤلفون: Antonarakis, ES, Piulats, JM, Gross-Goupil, M, Goh, JC, Vaishampayan, UN, De Wit, R, Alanko, TV, Fukasawa, S, Tabata, K, Feyerabend, S, Berger, R, Ojamaa, K, Hoimes, CJ, Sezer, A, Omlin, AG, Yachnin, J, Niu, C, Poehlein, CH, Schloss, C, de Bono, JS

المصدر: ANNALS OF ONCOLOGY. 32:S651-S652

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:147790274Test